SCHEMBL9285131

SCHEMBL9285131

CCCCOC(=O)N1CC[C@H](CO)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ GBA2 Q9HCG7 1/20 0.44
▸ GAA P10253 1/20 0.40
▸ GNAI3 P08754 2/20 0.38
▸ GNAO1 P09471 2/20 0.38
▸ GNAI1 P63096 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ P2RY12 Q9H244 2/20 0.38
▸ MMP3 P08254 2/20 0.38
▸ MMP9 P14780 2/20 0.38
▸ MMP13 P45452 2/20 0.38
▸ MMP1 P03956 1/20 0.38
▸ MMP7 P09237 1/20 0.38
▸ THRB P10828 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CHRM2 P08172 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724467 1.00 LMNA (0.51) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL29812927 0.91 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL4599962 0.91 SMN1; SMN2 (0.49) LMNAPOLBSMN1; SMN2GBA2ALDH1A1
SCHEMBL725320 0.91 LMNA (0.58) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL29813031 0.90 SMN1; SMN2 (0.48) LMNAPOLBSMN1; SMN2GBA2HPGD
SCHEMBL30380124 0.88 LMNA (0.49) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL4968757 0.87 LMNA (0.53) LMNAPOLBSMN1; SMN2GBA2HPGD
SCHEMBL9665931 0.87 SMN1; SMN2 (0.50) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL6119560 0.87 SMN1; SMN2 (0.50) LMNAPOLBSMN1; SMN2GBA2GAA
SCHEMBL10610075 0.86 GBA2 (0.49) LMNAPOLBSMN1; SMN2GBA2P2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760826-A1 CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND Theravance, Inc. (US) 2014-08-06 — — EP disclosed
WO-2013049617-A1 CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND THERAVANCE, INC. (US) 2013-04-04 — — WO disclosed
WO-2012075239-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-06-07 — — WO disclosed
Send feedback